Biggest Biotechnology Losers are NASDAQ: GNVC, ONCY, PARD

GenVec, Inc. (NASDAQ:GNVC) is down 9.02% to $2.42 on 1.03 million shares. The stock hit an intraday high and an intraday low of $2.54 and $2.37 respectively. In the last six months the stock went up over 212%. GenVec, Inc. is a clinical stage biopharmaceutical company developing gene-based therapeutic drugs and vaccines. Its lead product candidate, TNFerade biologic (TNFerade), is being developed for use in the treatment of cancer.

Subscribe to daily free stock newsletter by visiting:  http://www.pennystockpickreport.com/.

Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) declines 9.24% to $2.16. The stock hit an intraday high and an intraday low of $2.34 and $2.12 respectively. In the last six months the stock went up over 32%. Oncolytics Biotech Inc. is a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics.

Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) decreases 5.13% to $1.85. The stock hit an intraday high and an intraday low of $1.91 and $1.81 respectively. In the last six months the stock went down over 74%. Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of cancer therapy products. Its lead product candidate is picoplatin, a platinum-based cancer therapy.

About http://www.pennystockpickreport.com/

Penny Stock Pick Report offers a stock newsletter on OTC, PINKSHEETS ,OTCBB, and AMEX Stocks. Our subscribers receive daily up to date stock information on midcap, smallcap penny stocks and also stocks that are traded at NASDAQ and NYSE stock exchange. If you wish to feature your organization on our website then you can contact us at the email given below.